Pregnolia is developing a probe that improves care during routine pregnancy consultation. Positioned vaginally on the uterine cervix, the probe measures the stiffness of the tissue in only a few seconds.
As reported in a press release, Pregnolia has successfully closed its seed round at 3.25 million francs. The largest investor in the round was the investiere.ch platform, which contributed 1.7 million francs. Additional investors included Zürcher Kantonalbank and the software company CADFEM.
Furthermore, thanks to investiere.ch leveraging its network, Pregnolia was also able to gain two new board members: Bruno Reihl and Marc Kohler. Both have many years’ experience in the medtech and healthcare sectors. Bruno Reihl is a serial entrepreneur and the former CEO of the medtech company Raumedic. Marc Kohler was the CEO of the Spital Thurgau AG for the last 14 years.
Pregnolia has already produced a series of 1,000 devices together with renowned medical suppliers and has been conducting the relevant clinical testing. The startup was able to finance its first phase of development without the support of investors by using funds obtained through grants and prize money from numerous awards.
More News
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space